VBL Therapeutics

139 articles with VBL Therapeutics

• 

  BioSpace Movers & Shakers, Oct. 16

  10/16/2020

  Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.

• VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology, This Time for Treatment of Cancer

  10/15/2020

  VBL Therapeutics, announced that the European Patent Office has granted Patent #3328401, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology conditions.

• 

  BioSpace Global Roundup, Oct. 15

  10/15/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors

  10/13/2020

  VBL Therapeutics announced that it has appointed Marc Kozin as Vice Chairman of the Board.

• Newly Granted European Patent Protects VBL Therapeutics' Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036

  10/12/2020

  VBL Therapeutics, announced that the European Patent Office has granted Patent #3328408, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions.

• VBL Therapeutics to Present at the Chardan 4th Annual Genetic Medicines Conference

  9/29/2020

  VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, in a format of a fireside chat with analyst Geulah Livshits, PhD, at the Chardan 4th Annual Genetic Medicines Conference

• VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/21/2020

  VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually September 21-23, 2020. Presentation Details: Date: Wednesda

• VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conference

  9/15/2020

  - VBL Therapeutics (Nasdaq: VBLT ) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020.   " Our OVAL trial of VB-111 in ovarian cancer continues to progress well, with over a third of the study participants already enrolled, " said Dror Harats, MD, Chief Executive Officer of VBL Therapeutics.

• VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 Meeting

  9/11/2020

  VBL Therapeutics (Nasdaq: VBLT ), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). VBL's study is being presented at the MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting . Data show that VBL's anti-MOSPD2 mAbs significantly inhibited migration of monocytes isolate

• VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer

  9/10/2020

  VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer.

• 

  BioSpace Global Roundup, Sept. 10

  9/10/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601

  9/8/2020

  VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for VB-601.

• VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

  8/13/2020

  VBL Therapeutics announced financial results for the second quarter ended June 30, 2020, and provided a corporate update.

• VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer

  8/12/2020

  VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned interim analysis in the ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111) in patients with platinum-resistant ovarian cancer, and unanimously recommended that the study continue as planned.  In this second interim analysis, the DSMC reviewed unblinded Overall Survival (OS)

• VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13

  8/3/2020

  VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 13, 2020 at 8:30am Eastern Time to report second quarter ended June 30, 2020 financial results and to provide a corporate update. Thursday, August 13 @ 8:30amET From

• VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting

  6/22/2020

  The company's bi-specific antibody candidates significantly prolonged survival in models of metastatic human cervical and breast cancer

• 

  Clinical Catch-Up: May 31-June 5

  6/8/2020

  As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.

• VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress

  6/4/2020

  VBL Therapeutics, announced new data implicating the potential of its proprietary anti-MOSPD2 antibodies for treatment of rheumatoid arthritis.

• VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate

  6/1/2020

  OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. The DSMC recommended that the study proceed without modification.

• 

  ASCO Highlights: Takeda, Genentech, Johnson & Johnson and More

  6/1/2020

  The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.